PharmaCyte Biotech, Inc.
PharmaCyte Biotech is a biotechnology company developing cellular therapies for cancer, with a focus on pancreatic tumors, including locally advanced, inoperable, non-metastatic pancreatic cancer. Its Cell-in-a-Box® platform uses cellulose-based capsules to contain genetically engineered live human cells designed to convert a cancer prodrug into its cancer-killing form near a tumor. The current product candidate is CypCaps™. PharmaCyte’s development work also explores other applications of its prodrug/activator technology for cancer treatment. PharmaCyte is preparing product candidates for potential commercialization, but its therapies remain in development. Its proposed LAPC clinical trial is on FDA clinical hold. Austrianova manufactures the capsules and is the sole source of PharmaCyte’s product candidates; consultants handle its research and development work. The company has two full-time employees as of April 30, 2026. PharmaCyte is headquartered in Las Vegas, Nevada.
No SEC Form 4 filings for $PMCB in the last 30 days.
See all $PMCB insider activity →PharmaCyte Biotech, Inc. (PMCB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PharmaCyte Biotech, Inc. Announces Reverse Stock Split PharmaCyte’s common stock is expected to begin trading on a post-split adjusted basis on November 13, 2026 LAS VEGAS--(BUSINESS WIRE)—November 11, 2026—PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the
PharmaCyte Biotech (PMCB) reported $36.7M in total assets, including $17.7M in cash, and $27.5M in stockholders' equity as of July 31, 2026. The company plans to pursue investment opportunities and operational management, aiming to create shareholder value. PMCB focuses on developing cellular therapies for cancer, diabetes, and other diseases.
PharmaCyte Biotech (PMCB) approved a 1-for-19 reverse stock split, effective November 12, 2026. Outstanding shares will decrease from 10.8M to 566.1K. The split aims to meet Nasdaq's minimum bid-price requirement.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning PMCB (PharmaCyte Biotech, Inc.). Coverage has skewed bearish: 0 bullish, 4 neutral, and 1 bearish.
Recent PMCB coverage spans corporate actions, earnings and market movers.
The reverse split will increase the per‑share price, likely attracting investors and reducing price‑floor risk.
The modest cash position suggests limited near‑term financing capacity, potentially capping growth initiatives.
The reverse split reduces share count, potentially triggering short-term sell pressure but may improve compliance and price perception.
Earnings miss with zero revenue may pressure the stock further.
Near-term downside bias as the article frames continued sell-side consensus alongside a sharp low-price print.
AlphAI scores every news story that mentions PMCB with an AI model for sentiment and relevance, and aggregates insider trades from PharmaCyte Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PharmaCyte Biotech, Inc. (PMCB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PharmaCyte Biotech, Inc. Announces Reverse Stock Split PharmaCyte’s common stock is expected to begin trading on a post-split adjusted basis on November 13, 2026 LAS VEGAS--(BUSINESS WIRE)—November 11, 2026—PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the
PharmaCyte Biotech (PMCB) reported $36.7M in total assets, including $17.7M in cash, and $27.5M in stockholders' equity as of July 31, 2026. The company plans to pursue investment opportunities and operational management, aiming to create shareholder value. PMCB focuses on developing cellular therapies for cancer, diabetes, and other diseases.
PharmaCyte Biotech (PMCB) approved a 1-for-19 reverse stock split, effective November 12, 2026. Outstanding shares will decrease from 10.8M to 566.1K. The split aims to meet Nasdaq's minimum bid-price requirement.
PharmaCyte Biotech reported Q2 2026 revenue of $0 and a net loss of $5.79M, or $0.54 per share, improving from a $8.36M loss in the prior-year quarter. The company is addressing an FDA clinical hold, focusing on pancreatic cancer research, and reviewing a key partnership. Current cash is expected to last 12 months, but more capital may be needed for trials.
Nuvilex Inc. (NASDAQ:PMCB) shares fell 3.3% mid-day Wednesday to about $0.76, after trading as low as $0.76; the prior close was $0.7856. Volume was ~79,050 shares, down 74% from average. Analyst coverage cited by MarketBeat shows a consensus “Sell” rating, with Weiss Ratings reaffirming “sell (d)” and another firm also rating “sell.”
